You are here: Industry Insights > LEO Pharma

News List

LEO Pharma teams up with Wearifi for dermatology research wearable pharmaphorum
December 19, 2018
LEO Pharma is developing a wearable device based on miniature sensors and plans to assess its clinical potential in dermatology drug development.
Zymeworks and LEO Pharma Enter into Bispecific Antibody Licensing and Research Collaboration pharmafocusasia
December 04, 2018
Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional therapeutics, and LEO Pharma A/S, a global leader in medical dermatology.....
LEO Pharma and MorphoSys Expand Strategic Alliance to Develop Peptide-derived Therapeutics pharmafocusasia
December 03, 2018
LEO Pharma A/S, a global leader in medical dermatology, and MorphoSys AG today announced an expansion of their existing strategic alliance to include......
JW Pharmaceutical signs global out-licensing agreement for their novel atopic dermatitis drug candidate, JW1601, with LEO Pharma, a global leader in medical dermatology pharmafocusasia
November 27, 2018
W Pharmaceutical and LEO Pharma A/S announced today, that they have signed a global licensing agreement for JWP’s novel atopic dermatitis drug candidate....
JWP, LEO Pharma Sign Licensing Agreement contractpharma
August 28, 2018
JW Pharmaceutical (JWP) and LEO Pharma have signed a global licensing agreement for JWP’s novel atopic dermatitis drug candidate, JW1601, under which, LEO Pharma, a global leader in medical dermatology......
LEO Pharma to acquire Bayer’s prescription dermatology portfolio pharmaceutical-technology
August 03, 2018
Denmark-based LEO Pharma has signed a definitive agreement to acquire Bayer’s global prescription dermatology unit in a bid to expand its therapeutic areas and bolster a global footprint.
Bayer to sell prescription dermatology unit and transfer 450 employees to Leo Pharma fiercepharma
August 01, 2018
With an ambition to expand its position as a leading dermatology company, Leo Pharma has agreed to acquire Bayer’s prescription dermatology business, which delivered €280 million ($328 million) in 2017 sales.
HitGen enters into research collaboration with LEO Pharma biospectrumasia
August 09, 2017
The collaboration will discover novel small molecule leads for multiple therapeutic targets of interest to LEO Pharma
News of Note—GlaxoSmithKline’s R&D fix; Leo-HitGen deal; Stanford I-O pact fiercebiotech
August 08, 2017
GlaxoSmithKline’s R&D fix; Leo-HitGen deal; Stanford I-O pact
LEO Pharma gets EC nod for its first and only biologic Kyntheum that targets the IL-17 receptor biospectrumasia
July 27, 2017
By specifically binding to the receptor on skin cells rather than targeting free floating inflammatory mediators, brodalumab blocks the biological activity of several pro-inflammatory IL-17 cytokines involved in psoriasis plaque formation.

Previous page 1 2 3 Next page